Examining environmental toxicant exposure in firefighters

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects biomarker samples from firefighters before and after exposure to combustion emissions during structural fires. The aim is to assess the levels of toxicants, specifically focusing on substances like PAH, 1-HOP, PheT, and SPMA. Participants will provide urine samples to evaluate their exposure to these harmful substances, contributing to a better understanding of the health risks associated with firefighting. The study is designed to gather data without any interventions or treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Firefighter (career or volunteer)
* Over 18 years of age
* Able to provide written voluntary consent

Exclusion Criteria:

* Unwilling to provide a pre and post-exposure urine sample
* Current cancer diagnosis
* Tobacco use within the last 1 year (verified by urinary TNEs)

Where it's running

• Masonic Cancer Center
  Minneapolis, Minnesota, United States Recruiting

Study contacts

• Study coordinator: Joni Jensen
• Email: jense010@umn.edu
• Phone: 612-624-5178

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding NK Cell Function in Prostate Cancer Across Races

  This study tests whether natural killer (NK) cells behave differently in prostate cancer patients of diverse racial backgrounds by analyzing blood and tissue samples.

  Recruiting Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07910019

• Adapt NK cells for high-risk AML bridging to stem cell transplant

  This study tests an allogeneic NK cell infusion with a brief IL-2 boost in adults with relapsed or refractory AML to see if treatment can help prepare for a future stem cell transplant.

  Recruiting Phase 1/2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07591649

• FT536 injection for recurrent WHO Grade 4 astrocytoma

  This will try a single intratumoral dose of FT536, an off-the-shelf engineered NK‑cell therapy, in adults undergoing repeat surgery for recurrent Grade 4 astrocytoma.

  Recruiting Phase 1 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07560865

• GTB-5550 treatment for people with advanced solid tumors.

  This Phase 1 trial tests GTB-5550, a B7-H3-targeting natural killer (NK) cell engager, in adults with advanced solid tumors who have exhausted or are ineligible for standard treatments.

  Recruiting Phase 1 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07541573

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• UNTOLD: Survey on Unmet Needs After Ovarian Cancer

  This project will ask people who have had ovarian cancer to complete a one-time survey (and some a follow-up interview) to learn about ongoing concerns and unmet needs.

  Recruiting Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07070726

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.